ROCKWELL MEDICAL, INC. Cost of Revenue
ROCKWELL MEDICAL, INC. (RMTI) reported Cost of Revenue of $14.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-13
- ROCKWELL MEDICAL, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $14.54M, a 7.14% increase year-over-year.
- ROCKWELL MEDICAL, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $14.44M, a 9.03% decline year-over-year.
- ROCKWELL MEDICAL, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $14.47M, a 31.22% decline year-over-year.
- ROCKWELL MEDICAL, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $13.65M, a 38.15% decline year-over-year.
- ROCKWELL MEDICAL, INC. cost of goods and services sold for fiscal 2025 was $57.56M, a 31.48% decline from fiscal 2024.
- ROCKWELL MEDICAL, INC. cost of goods and services sold for fiscal 2024 was $84.00M, a 12.14% increase from fiscal 2023.
- ROCKWELL MEDICAL, INC. cost of goods and services sold for fiscal 2023 was $74.91M, a 8.98% increase from fiscal 2022.
- ROCKWELL MEDICAL, INC. cost of goods and services sold for fiscal 2022 was $68.73M, a 6.81% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.54M 10-Q · filed 2026-08-13 | $28.98M 10-Q · filed 2026-08-13 | $43.44M derived: sum of 3 quarters · filed 2026-08-13 | $57.10M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $14.44M 10-Q · filed 2026-05-07 | $28.91M derived: sum of 2 quarters · filed 2026-05-07 | $42.56M derived: sum of 3 quarters · filed 2026-05-07 | $56.13M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $14.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $28.12M derived: sum of 2 quarters · filed 2026-03-26 | $41.69M derived: sum of 3 quarters · filed 2026-08-13 | $57.56M 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | $13.65M 10-Q · filed 2025-11-12 | $27.22M derived: sum of 2 quarters · filed 2026-08-13 | $43.09M 10-Q · filed 2025-11-12 | $64.13M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $13.57M 10-Q · filed 2026-08-13 | $29.44M 10-Q · filed 2026-08-13 | $50.47M derived: sum of 3 quarters · filed 2026-08-13 | $72.55M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $15.87M 10-Q · filed 2026-05-07 | $36.91M derived: sum of 2 quarters · filed 2026-05-07 | $58.98M derived: sum of 3 quarters · filed 2026-05-07 | $80.27M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $21.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $43.11M derived: sum of 2 quarters · filed 2026-03-26 | $64.39M derived: sum of 3 quarters · filed 2026-03-26 | $84.00M 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | $22.08M 10-Q · filed 2025-11-12 | $43.36M derived: sum of 2 quarters · filed 2025-11-12 | $62.97M 10-Q · filed 2025-11-12 | $82.19M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $21.28M 10-Q · filed 2025-08-14 | $40.89M 10-Q · filed 2025-08-14 | $60.12M derived: sum of 3 quarters · filed 2025-08-14 | $81.69M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $19.61M 10-Q · filed 2025-05-12 | $38.84M derived: sum of 2 quarters · filed 2025-05-12 | $60.40M derived: sum of 3 quarters · filed 2025-05-12 | $77.45M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $19.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $40.79M derived: sum of 2 quarters · filed 2025-03-20 | $57.84M derived: sum of 3 quarters · filed 2025-03-20 | $74.91M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $21.57M 10-Q · filed 2024-11-12 | $38.62M derived: sum of 2 quarters · filed 2024-11-12 | $55.69M 10-Q · filed 2024-11-12 | $72.66M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $17.05M 10-Q · filed 2024-08-08 | $34.12M 10-Q · filed 2024-08-08 | $51.09M derived: sum of 3 quarters · filed 2024-08-08 | $69.00M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $17.07M 10-Q · filed 2024-05-14 | $34.04M derived: sum of 2 quarters · filed 2024-05-14 | $51.96M derived: sum of 3 quarters · filed 2024-05-14 | $68.89M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $16.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $34.89M derived: sum of 2 quarters · filed 2024-03-21 | $51.82M derived: sum of 3 quarters · filed 2024-03-21 | $68.73M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $17.91M 10-Q · filed 2023-11-14 | $34.85M derived: sum of 2 quarters · filed 2023-11-14 | $51.76M 10-Q · filed 2023-11-14 | $69.32M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $16.94M 10-Q · filed 2023-08-14 | $33.85M 10-Q · filed 2023-08-14 | $51.41M derived: sum of 3 quarters · filed 2023-08-14 | $67.73M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $16.91M 10-Q · filed 2023-05-15 | $34.47M derived: sum of 2 quarters · filed 2023-05-15 | $50.79M derived: sum of 3 quarters · filed 2023-05-15 | $66.19M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $17.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $33.88M derived: sum of 2 quarters · filed 2023-03-30 | $49.28M derived: sum of 3 quarters · filed 2023-03-30 | $64.35M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $16.32M 10-Q · filed 2022-11-14 | $31.72M derived: sum of 2 quarters · filed 2022-11-14 | $46.79M 10-Q · filed 2022-11-14 | $61.57M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $15.40M 10-Q · filed 2022-08-15 | $30.47M 10-Q · filed 2022-08-15 | $45.25M derived: sum of 3 quarters · filed 2022-08-15 | $60.18M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $15.07M 10-Q · filed 2022-05-16 | $29.85M derived: sum of 2 quarters · filed 2022-05-16 | $44.78M derived: sum of 3 quarters · filed 2022-05-16 | $59.80M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $14.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08 | $29.71M derived: sum of 2 quarters · filed 2022-04-08 | $44.73M derived: sum of 3 quarters · filed 2022-04-08 | $59.47M 10-K · filed 2022-04-08 | ||||
| 2020-09-30 | $14.93M 10-Q · filed 2021-11-15 | $29.95M derived: sum of 2 quarters · filed 2021-11-15 | $44.69M 10-Q · filed 2021-11-15 | $59.07M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $15.02M 10-Q · filed 2021-08-16 | $15.02M 10-Q · filed 2020-08-10 | $29.76M 10-Q · filed 2021-08-16 | $29.76M 10-Q · filed 2020-08-10 | $44.14M derived: sum of 3 quarters · filed 2021-08-16 | $59.56M derived: sum of 4 quarters · filed 2021-08-16 | ||
| 2020-03-31 | $14.74M 10-Q · filed 2021-05-17 | $14.74M 10-Q · filed 2020-05-11 | $29.12M derived: sum of 2 quarters · filed 2021-05-17 | $44.55M derived: sum of 3 quarters · filed 2021-05-17 | $58.66M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $14.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $29.80M derived: sum of 2 quarters · filed 2021-03-31 | $43.92M derived: sum of 3 quarters · filed 2021-03-31 | $58.46M 10-K · filed 2021-03-31 | $58.46M 10-K · filed 2020-03-17 | |||
| 2019-09-30 | $15.42M 10-Q · filed 2020-11-09 | $15.42M 10-Q · filed 2019-11-12 | $29.54M derived: sum of 2 quarters · filed 2020-11-09 | $44.09M 10-Q · filed 2020-11-09 | $44.09M 10-Q · filed 2019-11-12 | $59.76M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $14.11M 10-Q · filed 2020-08-10 | $28.66M 10-Q · filed 2020-08-10 | $44.33M derived: sum of 3 quarters · filed 2020-08-10 | $59.04M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $14.55M 10-Q · filed 2020-05-11 | $30.22M derived: sum of 2 quarters · filed 2020-05-11 | $44.92M derived: sum of 3 quarters · filed 2020-05-11 | $63.85M derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | $15.67M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-17 | $30.37M derived: sum of 2 quarters · filed 2020-03-17 | $49.30M derived: sum of 3 quarters · filed 2020-03-17 | $64.97M 10-K · filed 2020-03-17 | ||||
| 2018-09-30 | $14.70M 10-Q · filed 2019-11-12 | $33.63M derived: sum of 2 quarters · filed 2019-11-12 | $49.30M 10-Q · filed 2019-11-12 | $65.37M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-06-30 | $18.93M 10-Q · filed 2019-08-09 | $34.60M 10-Q · filed 2019-08-09 | $50.66M derived: sum of 3 quarters · filed 2019-08-09 | $64.22M derived: sum of 4 quarters · filed 2019-08-09 | ||||
| 2018-03-31 | $15.67M 10-Q · filed 2019-05-10 | $31.73M derived: sum of 2 quarters · filed 2019-05-10 | $45.29M derived: sum of 3 quarters · filed 2019-05-10 | $57.03M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2017-12-31 | $16.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $29.62M derived: sum of 2 quarters · filed 2019-03-18 | $41.36M derived: sum of 3 quarters · filed 2019-03-18 | $53.60M 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | $13.56M 10-Q · filed 2018-11-09 | $25.30M derived: sum of 2 quarters · filed 2018-11-09 | $37.54M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | $11.74M 10-Q · filed 2018-08-14 | $23.98M 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |